Kemwell signs agreement with European Company

Kemwell Biopharma announced that it has signed an agreement with a European company for the development and manufacture of monoclonal antibody therapeutics.


Kemwell Biopharma's development and manufacturing unit

Kemwell will provide a fully integrated solution including technology transfer, process industrialization, scale-up, manufacturing of toxicology materials, cGMP manufacturing of clinical materials and commercial manufacturing for both drug substance and fill & finish in vials from Kemwell's new state-of-the-art biopharmaceuticals facility in Bangalore.

"This broad development and manufacturing agreement demonstrates our customers' confidence in Kemwell's biotechnical capabilities. Partnering with a number of well-known technology providers, Kemwell aims to establish itself as a leading player in the one-stop-shop biopharmaceutical contract manufacturing space.

"Our over 30-year expertise in the pharmaceutical development and manufacturing space will help us provide high quality services and products at competitive prices to the biotech industry. We are also expecting an inspection from a European agency for our biopharmaceutical drug substance as well as fill-finish facility, during the second half of this year," said Mr Anurag Bagaria, managing director, Kemwell Biopharma.

In 2008, Kemwell entered into a strategic collaboration with Boehringer Ingelheim, Germany. These facilities have been designed with the engineering and operational support of Boehringer Ingelheim.

Kemwell Biopharma is an Indian global contract development and manufacturing company. The company develops and manufactures bio-pharmaceuticals for pharmaceutical organizations.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email